Publication details

Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia

Investor logo
Investor logo
Authors

KREJČÍ Marta DOUBEK Michael DUŠEK Jaroslav BRYCHTOVÁ Yvona RÁČIL Zdeněk NAVRÁTIL Milan TOMIŠKA Miroslav HORKÝ Ondřej POSPÍŠILOVÁ Šárka MAYER Jiří

Year of publication 2013
Type Article in Periodical
Magazine / Source Annals of hematology
MU Faculty or unit

Faculty of Medicine

Citation
Web http://dx.doi.org/10.1007/s00277-013-1790-5
Doi http://dx.doi.org/10.1007/s00277-013-1790-5
Field Oncology and hematology
Keywords Acute myeloid leukemia; Reduced-intensity conditioning; Fludarabine; Cytarabine; Amsacrine; Allogeneic transplantation
Attached files
Description Sequential use of chemotherapy and reduced-intensity conditioning (RIC) with allogeneic stem cell transplantation (SCT) has been proposed to improve the treatment outcomes in patients with high-risk acute myeloid leukemia (AML). Here, we present our experience with this procedure in a cohort of 60 AML patients with primary induction failure (n=9); early, refractory, or >= second relapse (n=41); or unfavorable cytogenetics (n=10). A combination of fludarabine (30 mg/m(2)/day), cytarabine (2 g/m(2)/day), and amsacrine (100 mg/m(2)/day) for 4 days was used. After 3 days of rest, RIC was carried out, consisting of 4 Gy total body irradiation, antithymocyte globulin (ATG-Fresenius), and cyclophosphamide (fludarabine, amsacrine, and cytarabine (FLAMSA)-RIC protocol). Prophylactic donor lymphocyte infusions (pDLIs) were given in patients with complete remission (CR) and without evidence of graft-versus-host disease >= 120 days after SCT. The median time of neutrophil engraftment was 17 days. CR was achieved in 47 of 60 patients (78 %). Eleven patients received pDLIs resulting in longterm CR in eight of them. Non-relapse mortality after 1 and 3 years was 25 and 28 %, respectively. With a median follow-up of 37 months (range, 10-69), 3-year overall survival and 3-year progression-free survival were 42 and 33%, respectively. In a multivariate analysis, dose of CD34(+) cells >5x10(6)/kg (p=0.005; hazard ratio (HR)=0.276), remission of AML before SCT (p=0.044; HR=0.421), and achievement of complete chimerism after SCT (p=0.001; HR=0.205) were significant factors of better overall survival. The use of the FLAMSA-RIC protocol in suitable high-risk AML patients results in a long-term survival rate of over 40 %.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info